{"entity":{"id":"nct06043973","kind":"trial","name":"Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance","aka":[],"tldr":"A phase 3 trial of aumolertinib in lung cancer, run by Qianfoshan Hospital, now recruiting.","summary":"Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance is a phase 3, interventional study registered as NCT06043973 by Qianfoshan Hospital, with a registry enrolment figure of 98 participants, started 2023-09-01 and due to reach its primary completion in 2026-09-01. Interventions recorded: almonertinib. Conditions listed: Advanced Non-small Cell Lung Cancer. Primary outcome: PFS. Lung eligibility wording from the registry: \"Metastatic Non-squamous NSCLC is histologically or cytologically proven to be inoperable and cannot receive radical concurrent chemoradiotherapy\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT06043973","url":"https://clinicaltrials.gov/study/NCT06043973"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["egfr-mutant-nsclc"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["aumolertinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06043973","phase":"3","setting":"A Prospective Single-center, Single-arm Clinical Study of Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation and TP53 Mutation","sponsor":"Qianfoshan Hospital","enrolled":98,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06043973/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"aumolertinib","kind":"drug","name":"Aumolertinib","route":"/drugs/aumolertinib/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}